-
Economic evaluation of nivolumab combined with ipilimumab in the first-line t...
The objective of this study was to evaluate the cost-effectiveness of nivolumab in combination with ipilimumab (nivo + ipi) compared to current therapeutic alternatives in... -
Pricing methods in outcome-based contracting: δ2: Willingness-to-pay-based pr...
Aims: Six Delta is a six-dimensional independent platform for outcome-based pricing/contracting. The second dimension (δ2) estimates prices on the basis of four... -
Burden of disease and costs associated with type 2 diabetes in emerging and e...
To estimate the clinical and economic burden of type 2 diabetes (T2D) in established (EST) and emerging markets (EMG). Three systematic literature reviews were conducted in... -
Disease burden on health care by pain severity and usual analgesic treatment ...
Osteoarthritis (OA) pain is a health care highly demanding and costing condition. To estimate disease burden on health care in OA in Spain, determining whether burden differs by... -
Cost-effectiveness and budget impact analysis of infliximab and its biosimila...
This study aimed to conduct a cost-effectiveness analysis of infliximab and its biosimilar compared to conventional therapy in refractory moderate-to-severe Crohn’s disease (CD)... -
Economic burden of subsequent fracture in osteoporosis patients in South Korea
This study aimed to assess the economic burden of subsequent fracture in osteoporosis patients with incident fracture. The authors conducted a retrospective cohort analysis of... -
Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the trea...
Background: Patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) have limited treatment options and poor prognoses. Tisagenlecleucel, a chimeric... -
A comparison of measurement properties between UK SF-6D and English EQ-5D-5L ...
Evidence is limited for comparative psychometric properties between EQ-5D-5L and SF-6D. Therefore, this study compared psychometric properties between those instruments using... -
Budget impact analysis of betrixaban for venous thromboembolism prophylaxis i...
Objectives: Venous thromboembolism (VTE) incurs substantial costs to the UK National Health Service (NHS). Betrixaban is approved in the US for VTE prophylaxis with a...
